Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer

Biomaterials

Volumn 101, Issue , 2016, Pages 321-340

  Zhang, Mingzhen ^a   Viennois, Emilie ^a   Prasad, Meena ^b,c   Zhang, Yunchen ^a   Wang, Lixin ^a,b   Zhang, Zhan ^a   Han, Moon Kwon ^a   Xiao, Bo ^a,d   Xu, Changlong ^a,e   Srinivasan, Shanthi ^b,c   Merlin, Didier ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOUTHWEST UNIVERSITY   (China)

^e THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colitis associated cancer; Edible ginger derived nanoparticles; Inflammatory bowel disease; Natural drug delivery system; Therapy

Indexed keywords

DISEASE CONTROL; FOOD ADDITIVES; MAMMALS; NANOPARTICLES; RNA;

COLITIS-ASSOCIATED CANCER; DRUG DELIVERY SYSTEM; INFLAMMATORY BOWEL DISEASE; INTESTINAL EPITHELIAL CELLS; NEGATIVE ZETA POTENTIALS; PRO-INFLAMMATORY CYTOKINES; SYNTHETIC NANOPARTICLES; THERAPY;

DISEASES;

(6) GINGEROL; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYCLIN D1; GINGER DERIVED NANOPARTICLE; HERBACEOUS AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; LIPID; MICRORNA; NANOPARTICLE; SHOGAOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT; CATECHOL DERIVATIVE; FATTY ALCOHOL; GINGEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; COLONIC SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; EDIBLE PLANT; FEMALE; GINGER; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; INTESTINE EPITHELIUM CELL; MACROPHAGE; MASS SPECTROMETRY; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SINGLE DRUG DOSE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; ULCERATIVE COLITIS; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; COLON TUMOR; COMPLICATION; HUMAN; INFLAMMATORY BOWEL DISEASE; PHYTOTHERAPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATECHOLS; CELL LINE; CELL LINE, TUMOR; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; FATTY ALCOHOLS; FEMALE; GINGER; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED C57BL; NANOPARTICLES; PHYTOTHERAPY;

EID: 84974533498     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.06.018     Document Type: Article

References (89)

1. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.
2. Chan A.T., Giovannucci E.L. Primary prevention of colorectal cancer. Gastroenterology 2010, 138:2029-2043.
3. Sussman D.A., Santaolalla R., Strobel S., Dheer R., Abreu M.T. Cancer in inflammatory bowel disease: lessons from animal models. Curr. Opin. Gastroenterol. 2012, 28:327-333.
4. Stretch G.L., Campbell B.J., Dwarakanath A.D., Yaqoob M., Stevenson A., Morris A.I., et al. 5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment. Pharm. Ther. 1996, 10:941-947.
5. Pertuit D., Moulari B., Betz T., Nadaradjane A., Neumann D., Ismaili L., et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control Release 2007, 123:211-218.
6. Hanauer S.B. New steroids for IBD: progress report. Gut 2002, 51:182-183.
7. Navaneethan U., Lashner B.A. Effects of immunosuppression and liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 2013, 11:524-525.
8. Wang D.Z., DuBois R.N. The role of anti-inflammatory drugs in colorectal cancer. Annu. Rev. Med. 2013, 64:131-144.
9. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012, 64:557-570.
10. Zhang S.F., Ermann J., Succi M.D., Zhou A., Hamilton M.J., Cao B.N., et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci. Transl. Med. 2015, 7:300ra128.
11. Xiao B., Laroui H., Viennois E., Ayyadurai S., Charania M.A., Zhang Y.C., et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014, 146:1289-1300.
12. Dulai P.S., Siegel C.A., Colombel J.F., Sandborn W.J., Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014, 63:1843-1853.
13. Moriasi C., Subramaniam D., Awasthi S., Ramalingam S., Anant S. Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor. Anti-Cancer Agent Med. Chem. 2012, 12:1221-1238.
14. Fukata M., Shang L.M., Santaolalla R., Sotolongo J., Pastorini C., Espana C., et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm. Bowel Dis. 2011, 17:1464-1473.
15. Xing X.H., Zhang B.B., Wang X.H., Liu F.J., Shi D.L., Cheng Y.S. An "imaging-biopsy" strategy for colorectal tumor reconfirmation by multipurpose paramagnetic quantum dots. Biomaterials 2015, 48:16-25.
16. Araujo F., Shrestha N., Shahbazi M.A., Liu D.F., Herranz-Blanco B., Makila E.M., et al. Microfluidic assembly of a multifunctional tailorable composite system designed for site specific combined oral delivery of peptide drugs. ACS Nano 2015, 9:8291-8302.
17. Hansen A.E., Petersen A.L., Henriksen J.R., Boerresen B., Rasmussen P., Elema D.R., et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using Copper-64 liposomes. ACS Nano 2015, 9:6985-6995.
18. Laroui H., Dalmasso G., Nguyen H.T.T., Yan Y.T., Sitaraman S.V., Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010, 138:843-853.
19. Han S.C., Cheng Q., Wu Y.D., Zhou J.H., Long X.W., Wei T., et al. Effects of hydrophobic core components in amphiphilic PDMAEMA nanoparticles on siRNA delivery. Biomaterials 2015, 48:45-55.
20. Xiao B., Yang Y., Viennois E., Zhang Y.C., Ayyadurai S., Baker M.T., et al. Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticles. J. Mater Chem. B 2014, 2:1499-1508.
21. Xiao B., Laroui H., Ayyadurai S., Viennois E., Charania M.A., Zhang Y.C., et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials 2013, 34:7471-7482.
22. Ramishetti S., Kedmi R., Goldsmith M., Leonard F., Sprague A.G., Godin B., et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 2015, 9:6706-6716.
23. Laroui H., Theiss A.L., Yan Y.T., Dalmasso G., Nguyen H.T.T., Sitaraman S.V., et al. Functional TNF alpha gene silencing mediated by polyethyleneimine/TNF alpha siRNA nanocomplexes in inflamed colon. Biomaterials 2011, 32:1218-1228.
24. Xiao B., Si X.Y., Zhang M.Z., Merlin D. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloid Surf. B 2015, 135:379-385.
25. Tang L., Tong R., Coyle V.J., Yin Q., Pondenis H., Borst L.B., et al. Targeting tumor vasculature with aptamer-functionalized doxorubicin - polylactide nanoconjugates for enhanced cancer therapy. ACS Nano 2015, 9:5072-5081.
26. Morton S.W., Lee M.J., Deng Z.J., Dreaden E.C., Siouve E., Shopsowitz K.E., et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal 2014, 7:ra44.
27. Zhuang X.Y., Deng Z.B., Mu J.Y., Zhang L.F., Yan J., Miller D., et al. Ginger-derived nanoparticles protect against alcohol-induced liver damage. J. Extracell. Vesicles 2015, 4:28713.
28. Mu J.Y., Zhuang X.Y., Wang Q.L., Jiang H., Deng Z.B., Wang B.M., et al. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol. Nutr. Food Res. 2014, 58:1561-1573.
29. Ju S.W., Mu J.Y., Dokland T., Zhuang X.Y., Wang Q.L., Jiang H., et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther. 2013, 21:1345-1357.
30. Wang B.M., Zhuang X.Y., Deng Z.B., Jiang H., Mu J.Y., Wang Q.L., et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol. Ther. 2014, 22:522-534.
31. Zhang M., Viennois E., Xu C., Merlin D. Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers 2016, 4:e1134415.
32. Brahmbhatt M., Gundala S.R., Asif G., Shamsi S.A., Aneja R. Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutr. Cancer 2013, 65:263-272.
33. Karna P., Chagani S., Gundala S.R., Rida P.C.G., Asif G., Sharma V., et al. Benefits of whole ginger extract in prostate cancer. Brit J. Nutr. 2012, 107:473-484.
34. Butt M.S., Sultan M.T. Ginger and its health claims: molecular aspects. Crit. Rev. Food Sci. 2011, 51:383-393.
35. Prasad S., Aggarwal B.B. Chronic diseases caused by chronic inflammation require chronic treatment: anti-inflammatory role of dietary spices. J. Clin. Cell Immunol. 2014, 2014.
36. Brown A.C., Shah C., Liu J., Pham J.T.H., Zhang J.G., Jadus M.R. Ginger's (Zingiber officinale roscoe) inhibition of rat colonic adenocarcinoma cells proliferation and angiogenesis in vitro. Phytother. Res. 2009, 23:640-645.
37. Grzanna R., Lindmark L., Frondoza C.G. Ginger - an herbal medicinal product with broad anti-inflammatory actions. J. Med. Food 2005, 8:125-132.
38. Al-Suhaimi E.A., Al-Riziza N.A., Al-Essa R.A. Physiological and therapeutical roles of ginger and turmeric on endocrine functions. Am. J. Chin. Med. 2011, 39:215-231.
39. Viennois E., Xiao B., Ayyadurai S., Wang L.X., Wang P.G., Zhang Q., et al. Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer. Lab. Invest. 2014, 94:950-965.
40. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 2009, 9:799-809.
41. Vetrano S., Rescigno M., Cera M.R., Correale C., Rumio C., Doni A., et al. Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 2008, 135:173-184.
42. Groschwitz K.R., Ahrens R., Osterfeld H., Gurish M.F., Han X.N., Abrink M., et al. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22381-22386.
43. Laroui H., Geem D., Xiao B., Viennois E., Rakhya P., Denning T., et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol. Ther. 2014, 22:69-80.
44. Hang T.T.N., Dalmasso G., Torkvist L., Halfvarson J., Yan Y.T., Laroui H., et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J. Clin. Invest. 2011, 121:1733-1747.
45. Francescone R., Hou V., Grivennikov S.I. Cytokines, IBD, and colitis-associated cancer. Inflamm. Bowel Dis. 2015, 21:409-418.
46. Peterson L.W., Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14:141-153.
47. Yan F., Cao H.W., Cover T.L., Whitehead R., Washington M.K., Polk D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
48. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
49. Marouga R., David S., Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem. 2005, 382:669-678.
50. Kakhniashvili D.G., Griko N.B., Bulla L.A., Goodman S.R. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp. Biol. Med. 2005, 230:787-792.
51. Leoni G., Neumann P.A., Kamaly N., Quiros M., Nishio H., Jones H.R., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J. Clin. Invest. 2015, 125:1215-1227.
52. Headland S.E., Jones H.R., Norling L.V., Kim A., Souza P.R., Corsiero E., et al. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. Sci. Transl. Med. 2015, 7:315ra190.
53. Saxena N.K., Taliaferro-Smith L., Knight B.B., Merlin D., Anania F.A., O'Regan R.M., et al. Bidirectional crosstalk between leptin and insulin-like growth Factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008, 68:9712-9722.
54. Yang S.Y., Chen J.Y., Zhao D., Han D.E., Chen X.J. Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency. Int. J. Pharm. 2012, 434:155-160.
55. Chassaing B., Srinivasan G., Delgado M.A., Young A.N., Gewirtz A.T., Vijay-Kumar M. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One 2012, 7:e44328.
56. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 1996, 184:241-251.
57. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-Deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
58. Viennois E., Baker M.T., Xiao B., Wang L.X., Laroui H., Merlin D. Longitudinal study of circulating protein biomarkers in inflammatory bowel disease. J. Proteomics 2015, 112:166-179.
59. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S.B., McIntire C.R., LeBlanc P.M., et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
60. De Robertis M., Massi E., Poeta M.L., Carotti S., Morini S., Cecchetelli L., et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J. Carcinog. 2011, 10:9.
61. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58:5071-5074.
62. Wiczer B.M., Thomas G. Phospholipase D and mTORC1: nutrients are what bring them together. Sci. Signal 2012, 5.
63. Record M. Exosome-like nanoparticles from food: protective nanoshuttles for bioactive cargo. Mol. Ther. 2013, 21:1294-1296.
64. Deol P.K., Kaur I.P. Improving the therapeutic efficiency of ginger extract for treatment of colon cancer using a suitably designed multiparticulate system. J. Drug Target 2013, 21:855-865.
65. Hsiang C.Y., Lo H.Y., Huang H.C., Li C.C., Wu S.L., Ho T.Y. Ginger extract and zingerone ameliorated trinitrobenzene sulphonic acid-induced colitis in mice via modulation of nuclear factor-kappa B activity and interleukin-1 beta signalling pathway. Food Chem. 2013, 136:170-177.
66. Prasad S., Tyagi A.K. Ginger and its constituents: role in prevention and treatment of gastrointestinal cancer. Gastroenterol. Res. Pract. 2015, 2015:142179.
67. Utrilla M.P., Peinado M.J., Ruiz R., Rodriguez-Nogales A., Algieri F., Rodriguez-Cabezas M.E., et al. Pea (Pisum sativum L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis. Mol. Nutr. Food Res. 2015, 59:807-819.
68. Fasolino I., Izzo A.A., Clavel T., Romano B., Haller D., Borrelli F. Orally administered allyl sulfides from garlic ameliorate murine colitis. Mol. Nutr. Food Res. 2015, 59:434-442.
69. Noubade R., Wong K., Ota N., Rutz S., Eidenschenk C., Valdez P.A., et al. NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature 2014, 509:235-239.
70. Rath E., Haller D. Mitochondria at the interface between danger signaling and metabolism: role of unfolded protein responses in chronic inflammation. Inflamm. Bowel Dis. 2012, 18:1364-1377.
71. Khounlotham M., Kim W., Peatman E., Nava P., Medina-Contreras O., Addis C., et al. Compromised intestinal epithelial barrier induces adaptive immune compensation that protects from colitis. Immunity 2012, 37:563-573.
72. Barrientos S., Stojadinovic O., Golinko M.S., Brem H., Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008, 16:585-601.
73. Kamekura R., Nava P., Feng M.L., Quiros M., Nishio H., Weber D.A., et al. Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. Mol. Biol. Cell 2015, 26:3165-3177.
74. Parkkila S., Parkkila A.K., Juvonen T., Rajaniemi H. Distribution of the carbonic-anhydrase Isoenzyme-I, isoenzyme-II, and isoenzyme-Vi in the human alimentary-tract. Gut 1994, 35:646-650.
75. Coombes J.L., Siddiqui K.R.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103(+) DCs induces Foxp3(+) regulatory T cells via a TGF-beta- and retinoic acid-dependent mechanism. J. Exp. Med. 2007, 204:1757-1764.
76. -) T cells. J. Immunol. 2012, 188:2164-2172.
77. -) T cells. J. Leukoc. Biol. 2013, 93:963-972.
78. Kitano M., Kudo M., Yamao K., Takagi T., Sakamoto H., Komaki T., et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. Am. J. Gastroenterol. 2012, 107:303-310.
79. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.
80. Rubin D.C., Shaker A., Levin M.S. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front. Immunol. 2012, 3:107.
81. Arthur J.C., Perez-Chanona E., Muhlbauer M., Tomkovich S., Uronis J.M., Fan T.J., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
82. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., et al. Sphingosine-1-Phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
83. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014, 345:235-241.
84. Kwon I.K., Wang R., Thangaraju M., Shuang H., Liu K., Dashwood R., et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 2010, 29:3423-3434.
85. Browning D.D., Kwon I.K., Wang R. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med. Chem. 2010, 2:65-80.
86. Li S.R., Gyselman V.G., Dorudi S., Bustin S.A. Elevated levels of RanBP7 mRNA in colorectal carcinoma are associated with increased proliferation and are similar to the transcription pattern of the proto-oncogene c-myc. Biochem. Biophys. Res. Commun. 2000, 271:537-543.
87. Hrabakova R., Kollareddy M., Tyleckova J., Halada P., Hajduch M., Gadher S.J., et al. Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy. J. Proteome Res. 2013, 12:455-469.
88. Lin Y., Buckhaults P.J., Lee J.R., Xiong H.R., Farrell C., Podolsky R.H., et al. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 2009, 11. 864-U209.
89. Yeo M., Kim D.K., Park H.J., Oh T.Y., Kim J.H., Cho S.W., et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 2006, 6:1158-1165.